Log in

NASDAQ:REGNRegeneron Pharmaceuticals Competitors & Alternatives

$627.25
+4.80 (+0.77 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$623.50
Now: $627.25
$639.00
50-Day Range
$544.01
MA: $599.20
$643.92
52-Week Range
$271.37
Now: $627.25
$646.33
Volume1.04 million shs
Average Volume1.33 million shs
Market Capitalization$69.01 billion
P/E Ratio31.52
Dividend YieldN/A
Beta0.58

Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) Vs. AMGN, GILD, CELG, VRTX, BIIB, and SGEN

Should you be buying REGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Regeneron Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Seattle Genetics (SGEN).

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals28.56%24.94%18.81%
Amgen32.03%90.75%15.44%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Regeneron Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0131312.56
Amgen1111602.54

Regeneron Pharmaceuticals currently has a consensus target price of $557.7037, indicating a potential downside of 11.09%. Amgen has a consensus target price of $246.08, indicating a potential downside of 3.97%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Regeneron Pharmaceuticals.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22
Amgen$23.36 billion6.45$7.84 billion$14.8217.29

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

68.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.8% of Amgen shares are held by institutional investors. 11.3% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Amgen beats Regeneron Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Gilead Sciences and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences3151002.25
Regeneron Pharmaceuticals0131312.56

Gilead Sciences currently has a consensus price target of $79.6538, suggesting a potential upside of 3.77%. Regeneron Pharmaceuticals has a consensus price target of $557.7037, suggesting a potential downside of 11.09%. Given Gilead Sciences' higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Valuation & Earnings

This table compares Gilead Sciences and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion4.29$5.39 billion$6.1412.50
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences21.84%35.44%12.84%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Insider and Institutional Ownership

80.2% of Gilead Sciences shares are held by institutional investors. Comparatively, 68.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Earnings & Valuation

This table compares Celgene and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22

Celgene has higher revenue and earnings than Regeneron Pharmaceuticals. Celgene is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Celgene and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene06002.00
Regeneron Pharmaceuticals0131312.56

Celgene currently has a consensus target price of $105.60, suggesting a potential downside of 2.44%. Regeneron Pharmaceuticals has a consensus target price of $557.7037, suggesting a potential downside of 11.09%. Given Celgene's higher possible upside, analysts plainly believe Celgene is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Celgene and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Insider and Institutional Ownership

71.7% of Celgene shares are held by institutional investors. Comparatively, 68.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.4% of Celgene shares are held by company insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Celgene has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Celgene on 8 of the 15 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.14$1.18 billion$4.2967.90
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vertex Pharmaceuticals and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
Regeneron Pharmaceuticals0131312.56

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, indicating a potential downside of 2.43%. Regeneron Pharmaceuticals has a consensus target price of $557.7037, indicating a potential downside of 11.09%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Volatility & Risk

Biogen has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Institutional and Insider Ownership

87.5% of Biogen shares are held by institutional investors. Comparatively, 68.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Biogen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen40.76%49.22%24.26%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Analyst Ratings

This is a summary of recent ratings for Biogen and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen517902.13
Regeneron Pharmaceuticals0131312.56

Biogen currently has a consensus price target of $308.7037, indicating a potential upside of 16.44%. Regeneron Pharmaceuticals has a consensus price target of $557.7037, indicating a potential downside of 11.09%. Given Biogen's higher possible upside, research analysts plainly believe Biogen is more favorable than Regeneron Pharmaceuticals.

Valuation & Earnings

This table compares Biogen and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion3.01$5.89 billion$33.577.90
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22

Biogen has higher revenue and earnings than Regeneron Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Regeneron Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seattle Genetics (NASDAQ:SGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Insider & Institutional Ownership

94.3% of Seattle Genetics shares are owned by institutional investors. Comparatively, 68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 31.1% of Seattle Genetics shares are owned by company insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Seattle Genetics and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seattle Genetics-32.81%-16.51%-13.88%
Regeneron Pharmaceuticals28.56%24.94%18.81%

Volatility and Risk

Seattle Genetics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Earnings and Valuation

This table compares Seattle Genetics and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seattle Genetics$916.71 million32.19$-158,650,000.00($1.33)-128.16
Regeneron Pharmaceuticals$7.86 billion8.78$2.12 billion$21.4729.22

Regeneron Pharmaceuticals has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Seattle Genetics and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seattle Genetics171212.62
Regeneron Pharmaceuticals0131312.56

Seattle Genetics currently has a consensus price target of $148.2778, suggesting a potential downside of 13.01%. Regeneron Pharmaceuticals has a consensus price target of $557.7037, suggesting a potential downside of 11.09%. Given Regeneron Pharmaceuticals' higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Seattle Genetics.

Summary

Regeneron Pharmaceuticals beats Seattle Genetics on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.2$256.25+0.8%$151.91 billion$23.36 billion20.08
Gilead Sciences logo
GILD
Gilead Sciences
2.0$76.76+0.5%$95.77 billion$22.45 billion19.73
Celgene logo
CELG
Celgene
1.7$108.24+0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$291.31+0.1%$75.48 billion$4.16 billion50.49
Biogen logo
BIIB
Biogen
1.9$265.12+0.1%$43.26 billion$14.38 billion8.18Analyst Report
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$170.45+0.8%$29.26 billion$916.71 million-90.66
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$113.57+1.1%$24.80 billion$4.99 billion10.69
Incyte logo
INCY
Incyte
1.4$107.79+1.2%$23.50 billion$2.16 billion-61.59
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$127.71+0.7%$22.93 billion$1.70 billion209.36Analyst Report
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$152.43+1.7%$17.43 billion$219.75 million-18.98
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$89.01+2.6%$12.99 billion$876.29 million-114.12
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$127.66+1.8%$11.64 billion$788.10 million69.38
Immunomedics logo
IMMU
Immunomedics
1.9$40.63+7.6%$8.67 billion$290,000.00-22.20Analyst Report
Heavy News Reporting
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$60.78+0.0%$8.50 billion$1.12 billion55.25
Exelixis logo
EXEL
Exelixis
1.9$23.48+0.1%$7.18 billion$967.78 million25.25Increase in Short Interest
Repligen logo
RGEN
Repligen
1.2$126.59+0.0%$6.62 billion$270.24 million281.32Decrease in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.7$119.04+1.1%$5.30 billion$1.45 billion9.93Analyst Downgrade
Novavax logo
NVAX
Novavax
1.2$79.44+2.8%$4.73 billion$18.66 million-19.19
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$85.77+2.0%$4.47 billion$1.11 billion65.98Heavy News Reporting
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55+0.3%$4.07 billion$182.24 million-11.96Insider Selling
Heavy News Reporting
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$27.99+1.9%$3.87 billion$195.99 million-50.89
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$32.94+2.0%$3.80 billion$23.87 million-11.76
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$57.84+0.3%$3.59 billion$36.13 million-53.06Unusual Options Activity
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.51+0.6%$3.18 billion$806.43 million-9.83
Alkermes logo
ALKS
Alkermes
1.1$19.59+0.9%$3.11 billion$1.17 billion-22.26
Opko Health logo
OPK
Opko Health
1.7$3.76+5.9%$2.37 billion$901.90 million-7.83Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$113.82+1.9%$1.79 billion$120.28 million-33.09
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$109.37+2.0%$1.72 billionN/A-16.06
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.18+0.1%$1.62 billion$428.41 million19.21
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$46.10+2.1%$1.59 billion$252 million-4.30High Trading Volume
Innoviva logo
INVA
Innoviva
0.9$13.80+1.4%$1.41 billion$261.02 million8.07
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$9.63+2.6%$1.36 billion$102.43 million-11.60
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$4.95+1.4%$885.53 million$48.83 million-5.27Analyst Report
Heavy News Reporting
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.58+2.8%$863.41 million$851.10 million-5.79Increase in Short Interest
Heavy News Reporting
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.89+0.2%$851.10 million$82.27 million-8.43
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.47+2.4%$799.24 million$35.22 million-4.60
Codexis logo
CDXS
Codexis
1.5$12.39+2.6%$712.37 million$68.46 million-49.56
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.23+0.3%$705.01 million$150,000.00-4.61
Agenus logo
AGEN
Agenus
1.5$3.96+1.5%$672.87 million$150.05 million-3.19
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.85+0.7%$646.42 million$227.19 million5.54Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
1.6$13.88+2.7%$617.82 million$22.27 million-6.40Analyst Downgrade
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.53+1.2%$508.31 million$143.01 million-0.91
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$62.31+0.2%$458.16 million$38.19 million18.71
Geron logo
GERN
Geron
1.2$2.13+1.9%$441.20 million$460,000.00-5.46
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.53+2.8%$399.49 million$109.33 million-2.94
MannKind logo
MNKD
MannKind
1.9$1.74+2.9%$381.52 million$63.04 million-7.57Analyst Downgrade
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10+0.0%$355.05 million$34.99 million-5.32
PDL BioPharma logo
PDLI
PDL BioPharma
1.0$2.91+2.4%$339.15 million$54.76 million-3.10
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.92+0.5%$323.65 million$59.29 million-12.00
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.9$12.61+1.4%$284.48 million$3.57 million-4.26Analyst Upgrade
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.